Skip to main content
Back to timeline
PharmaceuticalsSource publication:

Isomorphic Labs and MSD team up on oncology small molecules: IsoDDE designs, MSD runs the wet lab

Synopsis

Isomorphic Labs and MSD announced a research collaboration to discover small-molecule therapeutic candidates against one oncology indication of strategic importance. Isomorphic Labs will run in silico predictions and supply molecular designs using its proprietary drug-design engine IsoDDE, which in this collaboration draws on high-quality proprietary datasets selected and provided by MSD; MSD will handle preclinical and clinical development, manufacturing and commercialization. The agreement includes an upfront payment, payments tied to research, development, regulatory and commercialization milestones, and tiered royalties on net sales, and Isomorphic Labs holds an option to co-fund development in exchange for higher royalties.

AI-generated editorial illustration: Isomorphic Labs et MSD concluent une collaboration stratégique en matière de recherche

Interpretation

The two companies split the work between design and development: Isomorphic Labs handles in silico prediction and molecular design, while MSD handles preclinical and clinical development, manufacturing and commercialization. The object is a small-molecule therapeutic candidate for one oncology indication of strategic importance, not a marketed drug or an asset already in the clinic. The split is stated in the joint announcement and accompanied by remarks from Sarah Skerratt, head of research at Isomorphic Labs, and George Addona, senior vice president at MSD Research Laboratories.

The design side rests on IsoDDE, Isomorphic Labs' proprietary drug-design engine built from foundation AI models, which the company describes as modality-independent. The collaboration feeds IsoDDE high-quality proprietary datasets that MSD selected for this work, so predictions rest on the partner's data. The announcement describes IsoDDE as a computational drug-design system with the predictive fidelity needed to explore new biological systems, but gives no accuracy figure or benchmark comparison.

The payment structure separates cash into an upfront payment, contingent milestone payments and sales royalties, and Isomorphic Labs may co-fund development for higher royalties. The upfront payment is received on signing, while research, development, regulatory and commercialization milestones depend on reaching the corresponding points, and royalties are tiered on net sales. The announcement discloses no upfront amount, total milestone value or royalty rate, so these sums are potential revenue rather than received revenue.

Perspective

The announcement defines a collaboration to discover small-molecule therapeutic candidates for one oncology indication, with Isomorphic Labs doing in silico prediction and molecular design and MSD doing preclinical and clinical development, manufacturing and commercialization; it states no next experimental step or timeline.

The announcement discloses no upfront amount, total milestone value, royalty rate, target or indication name, and gives no design success rate or predictive accuracy; MSD's forward-looking statement explicitly says there is no guarantee that candidate products in development will obtain regulatory approval or achieve commercial success.